| A randomized trial of bevacizumab for newly diagnosed glioblastoma MR Gilbert, JJ Dignam, TS Armstrong, JS Wefel, DT Blumenthal, ... New England Journal of Medicine 370 (8), 699-708, 2014 | 3132 | 2014 |
| Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II … V Gondi, SL Pugh, WA Tome, C Caine, B Corn, A Kanner, H Rowley, ... Journal of Clinical Oncology 32 (34), 3810-3816, 2014 | 1176 | 2014 |
| Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma JC Buckner, EG Shaw, SL Pugh, A Chakravarti, MR Gilbert, GR Barger, ... New England Journal of Medicine 374 (14), 1344-1355, 2016 | 1098 | 2016 |
| Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial PD Brown, S Pugh, NN Laack, JS Wefel, D Khuntia, C Meyers, A Choucair, ... Neuro-oncology 15 (10), 1429-1437, 2013 | 980 | 2013 |
| Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001 PD Brown, V Gondi, S Pugh, WA Tome, JS Wefel, TS Armstrong, JA Bovi, ... Journal of Clinical Oncology 38 (10), 1019-1029, 2020 | 728 | 2020 |
| Radiation with or without antiandrogen therapy in recurrent prostate cancer WU Shipley, W Seiferheld, HR Lukka, PP Major, NM Heney, DJ Grignon, ... New England Journal of Medicine 376 (5), 417-428, 2017 | 694 | 2017 |
| Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology–RTOG 1203 AH Klopp, AR Yeung, S Deshmukh, KM Gil, L Wenzel, SN Westin, ... Journal of clinical oncology 36 (24), 2538-2544, 2018 | 309 | 2018 |
| RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results S Ryu, SL Pugh, PC Gerszten, FF Yin, RD Timmerman, YJ Hitchcock, ... Practical radiation oncology 4 (2), 76-81, 2014 | 309 | 2014 |
| Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma C Happold, T Gorlia, O Chinot, MR Gilbert, LB Nabors, W Wick, SL Pugh, ... Journal of Clinical Oncology 34 (7), 731-739, 2016 | 222 | 2016 |
| Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis B Levis, A Benedetti, JPA Ioannidis, Y Sun, Z Negeri, C He, Y Wu, ... Journal of clinical epidemiology 122, 115-128. e1, 2020 | 185 | 2020 |
| Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627) AB Lassman, SL Pugh, MR Gilbert, KD Aldape, S Geinoz, JH Beumer, ... Neuro-oncology 17 (7), 992-998, 2015 | 153 | 2015 |
| Quantifying unnecessary normal tissue complication risks due to suboptimal planning: a secondary study of RTOG 0126 KL Moore, R Schmidt, V Moiseenko, LA Olsen, J Tan, Y Xiao, J Galvin, ... International Journal of Radiation Oncology* Biology* Physics 92 (2), 228-235, 2015 | 144 | 2015 |
| Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539 CL Rogers, A Perry, S Pugh, MA Vogelbaum, D Brachman, W McMillan, ... Neuro-oncology 18 (4), 565-574, 2015 | 137 | 2015 |
| Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG/RTOG 9601 randomized clinical trial FY Feng, HC Huang, DE Spratt, SG Zhao, HM Sandler, JP Simko, ... JAMA oncology 7 (4), 544-552, 2021 | 119 | 2021 |
| Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study AR Yeung, SL Pugh, AH Klopp, KM Gil, L Wenzel, SN Westin, DK Gaffney, ... Journal of Clinical Oncology 38 (15), 1685-1692, 2020 | 117 | 2020 |
| NRG Oncology/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma CI Tsien, SL Pugh, AP Dicker, JJ Raizer, MM Matuszak, EC Lallana, ... Journal of Clinical Oncology 41 (6), 1285-1295, 2023 | 113 | 2023 |
| Feasibility of patient reporting of symptomatic adverse events via the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in a … E Basch, SL Pugh, AC Dueck, SA Mitchell, L Berk, S Fogh, LJ Rogak, ... International Journal of Radiation Oncology* Biology* Physics 98 (2), 409-418, 2017 | 103 | 2017 |
| Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG oncology RTOG 0525 EH Bell, SL Pugh, JP McElroy, MR Gilbert, M Mehta, AC Klimowicz, ... JAMA oncology 3 (6), 784-792, 2017 | 97 | 2017 |
| Institutional enrollment and survival among NSCLC patients receiving chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617 BR Eaton, SL Pugh, JD Bradley, G Masters, VS Kavadi, S Narayan, ... JNCI: Journal of the National Cancer Institute 108 (9), djw034, 2016 | 96 | 2016 |
| Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. JC Buckner, SL Pugh, EG Shaw, MR Gilbert, G Barger, S Coons, P Ricci, ... Journal of Clinical Oncology 32 (15_suppl), 2000-2000, 2014 | 91 | 2014 |
